WRS Therapeutics, a privately-held development-stage biotech company, is progressing a proprietary and novel platform oral drug delivery system. The company's technology is being developed as a solution for the two unresolved, and apparently unresolvable, holy grails of drug delivery: (1) the delivery of large molecule drugs through the oral route of administration; and (2) the targeted delivery of small and large molecule drugs to specific cells, tissues and organs. The company is currently undertaking formulation optimization and pre-clinical development (in vitro and in vivo) in collaboration with a number of academic researchers at universities in Australia. It intends to raise capital in early-2017 and establish its research and development operations, and its corporate head office, in the United States.